APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Coagulation Factor VIII

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Selected research

Market Outlook & Growth Opportunities

Global Human Coagulation Factor VIII Market Outlook and Growth Opportunities 2026

Report ID 17399958049 January 2026190 pages

Choose your research edition.

Industry ResearchHuman Coagulation Factor VIII Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Coagulation Factor VIII Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Human Coagulation Factor VIII Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Coagulation Factor VIII Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Coagulation Factor VIII Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.

This report provides an overview of the global Human Coagulation Factor VIII market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Human Coagulation Factor VIII and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Coagulation Factor VIII sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Coagulation Factor VIII market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Coagulation Factor VIII Segment by Company

Shire (Baxter)

Bayer

CSL

Pfizer

Grifols

Biogen

Octapharma

NovoNordisk

Greencross

Kedrion

BPL

Hualan Bio

RAAS

Human Coagulation Factor VIII Segment by Type

Recombinant Factor VIII

Plasma-derived Factor VIII

Human Coagulation Factor VIII Segment by Application

Hemophilia A

Spontanous / Trauma

Surgical

Other

Human Coagulation Factor VIII Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Coagulation Factor VIII status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Coagulation Factor VIII market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Coagulation Factor VIII significant trends, drivers, influence factors in global and regions.

6. To analyze Human Coagulation Factor VIII competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor VIII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor VIII and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor VIII.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Coagulation Factor VIII market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Coagulation Factor VIII industry.

Chapter 3: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Coagulation Factor VIII in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Coagulation Factor VIII Industry Trends Table 2. Human Coagulation Factor VIII Industry Drivers Table 3. Human Coagulation Factor VIII Industry Opportunities and Challenges Table 4. Human Coagulation Factor VIII Industry Restraints Table 5. Global Human Coagulation Factor VIII Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Coagulation Factor VIII Revenue Share by Company (2021-2026) Table 7. Global Human Coagulation Factor VIII Sales Volume by Company (K Bottles) & (2021-2026) Table 8. Global Human Coagulation Factor VIII Sales Volume Share by Company (2021-2026) Table 9. Global Human Coagulation Factor VIII Average Price (USD/Bottle) of Company (2021-2026) Table 10. Global Human Coagulation Factor VIII Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Coagulation Factor VIII Key Company Manufacturing Base & Headquarters Table 12. Global Human Coagulation Factor VIII Company, Product Type & Application Table 13. Global Human Coagulation Factor VIII Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Coagulation Factor VIII by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Factor VIII Table 18. Significant Companies of Plasma-derived Factor VIII Table 19. Global Human Coagulation Factor VIII Sales Volume by Type 2021 VS 2025 VS 2032 (K Bottles) Table 20. Global Human Coagulation Factor VIII Sales Volume by Type (2021-2026) & (K Bottles) Table 21. Global Human Coagulation Factor VIII Sales Volume by Type (2027-2032) & (K Bottles) Table 22. Global Human Coagulation Factor VIII Sales Volume Share by Type (2021-2026) Table 23. Global Human Coagulation Factor VIII Sales Volume Share by Type (2027-2032) Table 24. Global Human Coagulation Factor VIII Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Coagulation Factor VIII Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Human Coagulation Factor VIII Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Human Coagulation Factor VIII Sales Value Share by Type (2021-2026) Table 28. Global Human Coagulation Factor VIII Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hemophilia A Table 30. Significant Companies of Spontanous / Trauma Table 31. Significant Companies of Surgical Table 32. Significant Companies of Other Table 33. Global Human Coagulation Factor VIII Sales Volume by Application 2021 VS 2025 VS 2032 (K Bottles) Table 34. Global Human Coagulation Factor VIII Sales Volume by Application (2021-2026) & (K Bottles) Table 35. Global Human Coagulation Factor VIII Sales Volume by Application (2027-2032) & (K Bottles) Table 36. Global Human Coagulation Factor VIII Sales Volume Share by Application (2021-2026) Table 37. Global Human Coagulation Factor VIII Sales Volume Share by Application (2027-2032) Table 38. Global Human Coagulation Factor VIII Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human Coagulation Factor VIII Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Human Coagulation Factor VIII Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Human Coagulation Factor VIII Sales Value Share by Application (2021-2026) Table 42. Global Human Coagulation Factor VIII Sales Value Share by Application (2027-2032) Table 43. Global Human Coagulation Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (K Bottles) Table 44. Global Human Coagulation Factor VIII Sales by Region (2021-2026) & (K Bottles) Table 45. Global Human Coagulation Factor VIII Sales Market Share by Region (2021-2026) Table 46. Global Human Coagulation Factor VIII Sales by Region (2027-2032) & (K Bottles) Table 47. Global Human Coagulation Factor VIII Sales Market Share by Region (2027-2032) Table 48. Global Human Coagulation Factor VIII Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Coagulation Factor VIII Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Human Coagulation Factor VIII Sales Value Share by Region (2021-2026) Table 51. Global Human Coagulation Factor VIII Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Human Coagulation Factor VIII Sales Value Share by Region (2027-2032) Table 53. Global Human Coagulation Factor VIII Market Average Price (USD/Bottle) by Region (2021-2026) Table 54. Global Human Coagulation Factor VIII Market Average Price (USD/Bottle) by Region (2027-2032) Table 55. Global Human Coagulation Factor VIII Sales by Country: 2021 VS 2025 VS 2032 (K Bottles) Table 56. Global Human Coagulation Factor VIII Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Human Coagulation Factor VIII Sales by Country (2021-2026) & (K Bottles) Table 58. Global Human Coagulation Factor VIII Sales Market Share by Country (2021-2026) Table 59. Global Human Coagulation Factor VIII Sales by Country (2027-2032) & (K Bottles) Table 60. Global Human Coagulation Factor VIII Sales Market Share by Country (2027-2032) Table 61. Global Human Coagulation Factor VIII Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Human Coagulation Factor VIII Sales Value Market Share by Country (2021-2026) Table 63. Global Human Coagulation Factor VIII Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Human Coagulation Factor VIII Sales Value Market Share by Country (2027-2032) Table 65. Shire (Baxter) Company Information Table 66. Shire (Baxter) Business Overview Table 67. Shire (Baxter) Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 68. Shire (Baxter) Human Coagulation Factor VIII Product Portfolio Table 69. Shire (Baxter) Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 73. Bayer Human Coagulation Factor VIII Product Portfolio Table 74. Bayer Recent Development Table 75. CSL Company Information Table 76. CSL Business Overview Table 77. CSL Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 78. CSL Human Coagulation Factor VIII Product Portfolio Table 79. CSL Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 83. Pfizer Human Coagulation Factor VIII Product Portfolio Table 84. Pfizer Recent Development Table 85. Grifols Company Information Table 86. Grifols Business Overview Table 87. Grifols Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 88. Grifols Human Coagulation Factor VIII Product Portfolio Table 89. Grifols Recent Development Table 90. Biogen Company Information Table 91. Biogen Business Overview Table 92. Biogen Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 93. Biogen Human Coagulation Factor VIII Product Portfolio Table 94. Biogen Recent Development Table 95. Octapharma Company Information Table 96. Octapharma Business Overview Table 97. Octapharma Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 98. Octapharma Human Coagulation Factor VIII Product Portfolio Table 99. Octapharma Recent Development Table 100. NovoNordisk Company Information Table 101. NovoNordisk Business Overview Table 102. NovoNordisk Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 103. NovoNordisk Human Coagulation Factor VIII Product Portfolio Table 104. NovoNordisk Recent Development Table 105. Greencross Company Information Table 106. Greencross Business Overview Table 107. Greencross Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 108. Greencross Human Coagulation Factor VIII Product Portfolio Table 109. Greencross Recent Development Table 110. Kedrion Company Information Table 111. Kedrion Business Overview Table 112. Kedrion Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 113. Kedrion Human Coagulation Factor VIII Product Portfolio Table 114. Kedrion Recent Development Table 115. BPL Company Information Table 116. BPL Business Overview Table 117. BPL Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 118. BPL Human Coagulation Factor VIII Product Portfolio Table 119. BPL Recent Development Table 120. Hualan Bio Company Information Table 121. Hualan Bio Business Overview Table 122. Hualan Bio Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 123. Hualan Bio Human Coagulation Factor VIII Product Portfolio Table 124. Hualan Bio Recent Development Table 125. RAAS Company Information Table 126. RAAS Business Overview Table 127. RAAS Human Coagulation Factor VIII Sales (K Bottles), Value (US$ Million), Price (USD/Bottle) and Gross Margin (2021-2026) Table 128. RAAS Human Coagulation Factor VIII Product Portfolio Table 129. RAAS Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Human Coagulation Factor VIII Distributors List Table 133. Human Coagulation Factor VIII Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Human Coagulation Factor VIII Product Image Figure 2. Global Human Coagulation Factor VIII Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Coagulation Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Coagulation Factor VIII Sales (2021-2032) & (K Bottles) Figure 5. Global Human Coagulation Factor VIII Sales Average Price (USD/Bottle) & (2021-2032) Figure 6. Global Human Coagulation Factor VIII Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Factor VIII Image Figure 10. Plasma-derived Factor VIII Image Figure 11. Global Human Coagulation Factor VIII Sales Volume by Type (2021 VS 2025 VS 2032) & (K Bottles) Figure 12. Global Human Coagulation Factor VIII Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Human Coagulation Factor VIII Sales Volume Share by Type (2021-2032) Figure 14. Global Human Coagulation Factor VIII Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Coagulation Factor VIII Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Coagulation Factor VIII Sales Value Share by Type (2021-2032) Figure 17. Hemophilia A Image Figure 18. Spontanous / Trauma Image Figure 19. Surgical Image Figure 20. Other Image Figure 21. Global Human Coagulation Factor VIII Sales Volume by Application (2021 VS 2025 VS 2032) & (K Bottles) Figure 22. Global Human Coagulation Factor VIII Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Human Coagulation Factor VIII Sales Volume Share by Application (2021-2032) Figure 24. Global Human Coagulation Factor VIII Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Human Coagulation Factor VIII Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Human Coagulation Factor VIII Sales Value Share by Application (2021-2032) Figure 27. Global Human Coagulation Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (K Bottles) Figure 28. Global Human Coagulation Factor VIII Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Human Coagulation Factor VIII Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Human Coagulation Factor VIII Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Human Coagulation Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 32. North America Human Coagulation Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Human Coagulation Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Human Coagulation Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Human Coagulation Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Human Coagulation Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Human Coagulation Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 38. South America Human Coagulation Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Human Coagulation Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Human Coagulation Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Human Coagulation Factor VIII Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Human Coagulation Factor VIII Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Factor VIII
  • Plasma-derived Factor VIII
Applications
  • Hemophilia A
  • Spontanous / Trauma
  • Surgical
  • Other
Companies covered
  • Shire (Baxter)
  • Bayer
  • CSL
  • Pfizer
  • Grifols
  • Biogen
  • Octapharma
  • NovoNordisk
  • Greencross
  • Kedrion
  • BPL
  • Hualan Bio
  • RAAS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Coagulation Factor VIII Sales Value (2021-2032)
  4. 1.2.2 Global Human Coagulation Factor VIII Sales Volume (2021-2032)
  5. 1.2.3 Global Human Coagulation Factor VIII Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Coagulation Factor VIII Market Dynamics
  1. 2.1 Human Coagulation Factor VIII Industry Trends
  2. 2.2 Human Coagulation Factor VIII Industry Drivers
  3. 2.3 Human Coagulation Factor VIII Industry Opportunities and Challenges
  4. 2.4 Human Coagulation Factor VIII Industry Restraints
3 Human Coagulation Factor VIII Market by Company
  1. 3.1 Global Human Coagulation Factor VIII Company Revenue Ranking in 2025
  2. 3.2 Global Human Coagulation Factor VIII Revenue by Company (2021-2026)
  3. 3.3 Global Human Coagulation Factor VIII Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Coagulation Factor VIII Average Price by Company (2021-2026)
  5. 3.5 Global Human Coagulation Factor VIII Company Ranking (2024-2026)
  6. 3.6 Global Human Coagulation Factor VIII Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Coagulation Factor VIII Company Product Type and Application
  8. 3.8 Global Human Coagulation Factor VIII Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Coagulation Factor VIII Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Coagulation Factor VIII Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Coagulation Factor VIII Market by Type
  1. 4.1 Human Coagulation Factor VIII Type Introduction
  2. 4.1.1 Recombinant Factor VIII
  3. 4.1.2 Plasma-derived Factor VIII
  4. 4.2 Global Human Coagulation Factor VIII Sales Volume by Type
  5. 4.2.1 Global Human Coagulation Factor VIII Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Coagulation Factor VIII Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Human Coagulation Factor VIII Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Human Coagulation Factor VIII Sales Value by Type
  9. 4.3.1 Global Human Coagulation Factor VIII Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Coagulation Factor VIII Sales Value by Type (2021-2032)
  11. 4.3.3 Global Human Coagulation Factor VIII Sales Value Share by Type (2021-2032)
5 Human Coagulation Factor VIII Market by Application
  1. 5.1 Human Coagulation Factor VIII Application Introduction
  2. 5.1.1 Hemophilia A
  3. 5.1.2 Spontanous / Trauma
  4. 5.1.3 Surgical
  5. 5.1.4 Other
  6. 5.2 Global Human Coagulation Factor VIII Sales Volume by Application
  7. 5.2.1 Global Human Coagulation Factor VIII Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Coagulation Factor VIII Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Human Coagulation Factor VIII Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Human Coagulation Factor VIII Sales Value by Application
  11. 5.3.1 Global Human Coagulation Factor VIII Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Coagulation Factor VIII Sales Value by Application (2021-2032)
  13. 5.3.3 Global Human Coagulation Factor VIII Sales Value Share by Application (2021-2032)
6 Human Coagulation Factor VIII Regional Sales and Value Analysis
  1. 6.1 Global Human Coagulation Factor VIII Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Coagulation Factor VIII Sales by Region (2021-2032)
  3. 6.2.1 Global Human Coagulation Factor VIII Sales by Region: 2021-2026
  4. 6.2.2 Global Human Coagulation Factor VIII Sales by Region (2027-2032)
  5. 6.3 Global Human Coagulation Factor VIII Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Coagulation Factor VIII Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Coagulation Factor VIII Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Coagulation Factor VIII Sales Value by Region (2027-2032)
  9. 6.5 Global Human Coagulation Factor VIII Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Coagulation Factor VIII Sales Value (2021-2032)
  12. 6.6.2 North America Human Coagulation Factor VIII Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Coagulation Factor VIII Sales Value (2021-2032)
  15. 6.7.2 Europe Human Coagulation Factor VIII Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Coagulation Factor VIII Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Coagulation Factor VIII Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Coagulation Factor VIII Sales Value (2021-2032)
  21. 6.9.2 South America Human Coagulation Factor VIII Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Coagulation Factor VIII Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Coagulation Factor VIII Sales Value Share by Country, 2025 VS 2032
7 Human Coagulation Factor VIII Country-level Sales and Value Analysis
  1. 7.1 Global Human Coagulation Factor VIII Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Coagulation Factor VIII Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Coagulation Factor VIII Sales by Country (2021-2032)
  4. 7.3.1 Global Human Coagulation Factor VIII Sales by Country (2021-2026)
  5. 7.3.2 Global Human Coagulation Factor VIII Sales by Country (2027-2032)
  6. 7.4 Global Human Coagulation Factor VIII Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Coagulation Factor VIII Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Coagulation Factor VIII Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Coagulation Factor VIII Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Coagulation Factor VIII Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Coagulation Factor VIII Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shire (Baxter)
  2. 8.1.1 Shire (Baxter) Company Information
  3. 8.1.2 Shire (Baxter) Business Overview
  4. 8.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shire (Baxter) Human Coagulation Factor VIII Product Portfolio
  6. 8.1.5 Shire (Baxter) Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Human Coagulation Factor VIII Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 CSL
  14. 8.3.1 CSL Company Information
  15. 8.3.2 CSL Business Overview
  16. 8.3.3 CSL Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSL Human Coagulation Factor VIII Product Portfolio
  18. 8.3.5 CSL Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Human Coagulation Factor VIII Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Grifols
  26. 8.5.1 Grifols Company Information
  27. 8.5.2 Grifols Business Overview
  28. 8.5.3 Grifols Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Grifols Human Coagulation Factor VIII Product Portfolio
  30. 8.5.5 Grifols Recent Developments
  31. 8.6 Biogen
  32. 8.6.1 Biogen Company Information
  33. 8.6.2 Biogen Business Overview
  34. 8.6.3 Biogen Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Biogen Human Coagulation Factor VIII Product Portfolio
  36. 8.6.5 Biogen Recent Developments
  37. 8.7 Octapharma
  38. 8.7.1 Octapharma Company Information
  39. 8.7.2 Octapharma Business Overview
  40. 8.7.3 Octapharma Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Octapharma Human Coagulation Factor VIII Product Portfolio
  42. 8.7.5 Octapharma Recent Developments
  43. 8.8 NovoNordisk
  44. 8.8.1 NovoNordisk Company Information
  45. 8.8.2 NovoNordisk Business Overview
  46. 8.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 NovoNordisk Human Coagulation Factor VIII Product Portfolio
  48. 8.8.5 NovoNordisk Recent Developments
  49. 8.9 Greencross
  50. 8.9.1 Greencross Company Information
  51. 8.9.2 Greencross Business Overview
  52. 8.9.3 Greencross Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Greencross Human Coagulation Factor VIII Product Portfolio
  54. 8.9.5 Greencross Recent Developments
  55. 8.10 Kedrion
  56. 8.10.1 Kedrion Company Information
  57. 8.10.2 Kedrion Business Overview
  58. 8.10.3 Kedrion Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Kedrion Human Coagulation Factor VIII Product Portfolio
  60. 8.10.5 Kedrion Recent Developments
  61. 8.11 BPL
  62. 8.11.1 BPL Company Information
  63. 8.11.2 BPL Business Overview
  64. 8.11.3 BPL Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 BPL Human Coagulation Factor VIII Product Portfolio
  66. 8.11.5 BPL Recent Developments
  67. 8.12 Hualan Bio
  68. 8.12.1 Hualan Bio Company Information
  69. 8.12.2 Hualan Bio Business Overview
  70. 8.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hualan Bio Human Coagulation Factor VIII Product Portfolio
  72. 8.12.5 Hualan Bio Recent Developments
  73. 8.13 RAAS
  74. 8.13.1 RAAS Company Information
  75. 8.13.2 RAAS Business Overview
  76. 8.13.3 RAAS Human Coagulation Factor VIII Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 RAAS Human Coagulation Factor VIII Product Portfolio
  78. 8.13.5 RAAS Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Coagulation Factor VIII Value Chain Analysis
  2. 9.1.1 Human Coagulation Factor VIII Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Coagulation Factor VIII Sales Mode & Process
  6. 9.2 Human Coagulation Factor VIII Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Coagulation Factor VIII Distributors
  9. 9.2.3 Human Coagulation Factor VIII Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst